YP3A4 is involved in the metabolism of the anticonvulsant gabapentin, which is used to treat neuropathic pain and epilepsy. It may be oxidised using this enzyme to produce gabapentinol or norgabapentinol.It was first authorised as Neurontin in 1993 and reapproved as Gabapentin in 2005.
